Mr. Bullock is a leader in the cardiac rhythm management field and has served as Chief Executive Officer of Atritech, an electrophysiology company that was acquired by Boston Scientific in 2011, and Endocardial Solutions, a catheter-based cardiac mapping company that was acquired by St. Jude Medical in 2005.

In conjunction with this appointment, CardioInsight has announced that Steve Arless will be leaving his role as Chairman, and Chief Executive Officer. The Board of Directors expresses its appreciation for Mr. Arless’ service to the Company during his tenure.

Under Mr. Bullock’s direction, Dr. Charu Ramanathan, Co-Founder & Chief Scientific Officer, will function as interim President, and will lead the newly formed Office of the President. Joining Dr. Ramanathan in the Office of the President will be Kevin Mendelsohn, VP of Finance & Corporate Development, and together they will manage the leadership responsibilities of the Company. “The Company is well positioned, and Charu and Kevin are prepared to lead the company through this next phase in its development,” said Mr. Bullock. “CardioInsight’s non-invasive mapping system has demonstrated the ability to uniquely address clear unmet need in the diagnosis and treatment of patients with cardiac arrhythmias and heart failure, and we look forward to further validating the benefits of this platform in day-to-day clinical practice.”

 ****
About CardioInsight Technologies Inc.
CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. The Company’s ECVUE system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans. It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hospital Cardiologique Haut Leveque in Bordeaux, France. These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system. Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences. The Company has received its CE Mark and markets the ECVUE system in Europe.

CardioInsight Announces Closing of $7.5 Million Equity Financing

Cleveland, OH, March 14, 2012 – CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the closing of a $7.5 million Series “C” financing.  The proceeds from the financing will help CardioInsight accelerate clinical and commercial efforts related to its ECVUE™ advanced 3D cardiac mapping system. 

CardioInsight recently announced its CE Mark certification and the successful installation of the ECVUE System at its first clinical customer sites.  In the coming months, the Company will focus on securing its FDA regulatory clearance, demonstrating the value of the ECVUE System to improve the mapping of arrhythmias in routine clinical use, and proving its value in Cardiac Resynchronization Therapy (CRT).

“Securing this additional investment provides CardioInsight the ability to accelerate its clinical development and further demonstrate the commercial value of the ECVUE System,” said Steve Arless, CEO of CardioInsight.  “Over the next twelve to eighteen months, we will present a growing body of evidence demonstrating the strong clinical utility of our system; ultimately laying the foundation for commercial expansion in Europe and commercial introduction in the U.S.”

CardioInsight has successfully completed commercial installations at three leading centers in Europe, including St. Mary’s Hospital in London, England, the Kerckhoff Clinic in Bad Nauheim, Germany and the Hopital Cardiologique du Haut-Leveque in Bordeaux, France.  This increased clinical use will highlight the ECVUE System’s ability to simplify cardiac mapping procedures, reduce procedure time, and expand the use of mapping to new applications, including cardiac resynchronization for heart failure.

****

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. The Company’s ECVUE System non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans. It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hopital Cardiologique Haut Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE System.  Results of the studies have been published in leading peer-reviewed journals and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE System in Europe.

For more information, visit CardioInsight’s website at www.cardioinsight.com, or contact us at 216-453-5950.

CardioInsight Announces Addition of Jim Hassett to Senior Management Team

Cleveland, OH, February 28, 2012 – CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Jim Hassett as its Vice President of Clinical Affairs.

Mr. Hassett brings more than 30 years of product development, clinical development and regulatory affairs experience in the field of cardiac rhythm management to CardioInsight.  His previous roles include senior management level positions in clinical and therapy development, most notably at Daig Corporation and subsequently at St Jude Medical, where he held Vice President positions in the AF Division.  Mr. Hassett has successfully managed the development and clinical introduction of a number of innovative electrophysiology products that include cardiac mapping, arrhythmia ablation, and heart failure devices.

“I have been aware of CardioInsight’s technology for a number of years, and have been impressed with its development into a commercial product,” said Mr. Hassett.  “The ECVUE™  system addresses a clear unmet need in the treatment of arrhythmias and other electrical disorders of the heart, and I look forward to helping make this system a valuable clinical tool in everyday electrophysiology practice.”

CardioInsight recently announced the commercial introduction of its ECVUE non-invasive cardiac mapping system in Europe, and is working to demonstrate the clinical utility of the system in a commercial setting.   In the coming year, the Company will pursue regulatory clearance in the U.S., as well as accelerate its clinical development efforts to further validate its unique ability to simplify cardiac mapping procedures, reduce procedure times, and expand the use of mapping to new applications, including cardiac resynchronization therapy (CRT).

“Jim’s extensive clinical development experience, coupled with his strong reputation working with the FDA and clinical thought leaders throughout the world will be an invaluable asset as we accelerate our clinical development,” said Steve Arless, CardioInsight’s Chief Executive Officer. “The ability to attract someone of Jim’s caliber is further validation of the potential of the ECVUE system, and CardioInsight’s continued evolution to a commercial stage company.”

                                                                                                                                                                                                             ****

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart.  The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. The Company’s ECVUE system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans. It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hospital Cardiologique Haut Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE system in Europe.

For more information, visit CardioInsight’s website at www.cardioinsight.com, or contact us at 216-453-5950.

"We are excited to be CardioInsight’s first commercial partner and I was very impressed with the ECVUE system’s unique ability to display global cardiac activation without the need for an invasive study,” said Dr. Prapa Kanagaratnam, the Clinical Lead for Cardiac Electrophysiology at St. Mary’s Hospital, Imperial College Healthcare. “I think there is a real potential that this could be a disruptive technology that produces a paradigm shift in our approach to managing patients with cardiac arrhythmias.”

St. Mary’s Hospital has long been recognized as a leading institution in the study of cardiac electrophysiology, dating back to the first systematic clinical use of electrical recordings of the heart’s activity in the early 1900’s.  Dr. Davies and his team later became a pioneering center for catheter-based 3D mapping.

"We are proud to have the opportunity to work with the world-class team from St. Mary's Hospital as we look to demonstrate the clinical impact of the ECVUE system,” said Steve Arless, CEO of CardioInsight.  “I believe their commitment to help pioneer our non-invasive mapping system is a testament to the ECVUE system’s clinical potential, and we look forward to further demonstrating this potential under their guidance."

The commercial installation at St. Mary’s Hospital is the first of a focused commercial introduction of the ECVUE system in Europe to demonstrate the unique ability to simplify cardiac mapping procedures, reduce procedure time, and expand the use of mapping to new applications.

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart.  The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. The Company’s ECVUE system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3-D anatomical data obtained from imaging scans. It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hospital Cardiologique Haut Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE system in Europe.

For more information contact us at 216-453-5950.

CardioInsight featured on WKYC

Read the complete story on WKYC.

November 30, 2011, Cleveland, Ohio - CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today CE Mark clearance and the European commercial launch of its ECVUE™System to aid in the diagnosis of cardiac arrhythmias. In conjunction with this commercial launch, CardioInsight announced that it has secured its first three clinical customers, which include Dr. Wyn Davies at St. Mary’s Hospital in London, England, Dr. Heinz-Friedrich Pitschner at the Kerckhoff Heart and Lung Center in Bad Nauheim, Germany, and Dr. Michel Haissaguerre at Hôpital Cardiologique du Haut–Lévèquein Bordeaux, France.

CardioInsight’s patented ECVUE technology gathers electrical information from an electrode “vest” placed on a patient’s body and combines the information with images from a CT scan to produce 3D “electrical maps” of the patient’s heart. It is the first non-invasive, real-time, single beat, mapping solution to potentially improve the diagnosis and treatment of electrical abnormalities of the heart, including cardiac arrhythmias and congestive heart failure.

“Receiving the CE Mark is a significant milestone, and validates the ECVUE technology’s evolution to a commercial-ready product,” said Chief Executive Officer Steve Arless.  “We are excited to have attracted the interest of world-renowned clinicians as our first commercial customers, and are eager to continue to validate the technology’s unique clinical value proposition.”

To date, CardioInsight has completed more than 390 patient studies at leading clinical centers in the United States and Europe.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology called Electrocardiographic
Mapping (ECM) that non-invasively generates 3D images of the electrical activity of the heart.
The images help physicians more accurately treat certain heart ailments such as arrhythmias
and congestive heart failure. ECM non-invasively generates real-time, whole heart images of
the electrical activity on the surface of the heart by combining body surface electrical data with
3-D anatomical data obtained from imaging scans. CardioInsight’s ECVUE system reconstructs and
displays 3D images and other useful measures of cardiac electrical activity as if the
measurements were taken directly from the surface of the heart. The Company has received its CE Mark and markets the ECVUE system in Europe.

For more information, visit CardioInsight’s website at www.cardioinsight.com, or contact us at 216-453-5950.

Advanced cardiac imaging company gets $1 million Ohio loan

Noninvasive cardiac imaging company CardioInsight Technologies has added another $1 million ahead of an August product launch in Europe.

The Cleveland-based developer of new innovative medical devices was awarded a $1 million loan from the State of Ohio that will use to help commercialize its technology. CardioInsight expects to receive European regulatory clearance in August and then begin selling its technology there shortly afterwards, CEO Steve Arless said.

CardioInsight’s electrocardiographic mapping technology, which it calls ECVUE, gathers electrical information about the heart from an electrode ’vest’ placed on a patient’s body. It combines that information with images from a CT scan to produce 3-D maps of the electrical activity of the heart. Unlike conventional methods, CardioInsight’s technology is noninvasive and provides beat-by-beat, whole-heart mapping.

The technology could help diagnose and treat electrical abnormalities of the heart, such as those associated with arrhythmia and heart failure.

The low-interest loan was approved by Ohio’s Development Financing Advisory Council. To receive the loan from the state CardioInsight is required to contribute a $1 million match, according to a spokeswoman for the Ohio Department of Development.

CardioInsight has raised a total of about $12 million in investment funding since it was founded in 2006, Mr. Arless said. He summed up the Company’s value proposition in a video made a couples years ago for one of its investors, JumpStart Ventures.

"I'm trying to compare the new technology with my old experience, and sometimes it's helpful, and sometimes" it isn't, Nudelman says. But, the Russia native adds, blue eyes brightening, "It's the future."

STORY: Areas tie economic futures to industry clusters
Northeast Ohio is among a growing number of regions that are combating the loss of traditional factory jobs by developing industry clusters in fields such as biomedicine, renewable energy and aerospace. Besides medical devices, the Cleveland area — a more than century-old stronghold for auto, rubber and glass making — aims to carve out niches in clean energy and flexible electronics.

Hubs that group manufacturers, suppliers, training programs, researchers and others in the same region, aren't new. Hot beds such as computers in Silicon Valley, biotechnology in Boston and film in Hollywood developed organically and have thrived for decades.

But with the loss of 8.7 million jobs in the recession, state and local officials are more active in trying to speed the growth of nascent clusters to create new jobs. Emerging industry centers include electric-car batteries in Michigan, clean energy in Colorado and robotics in Pittsburgh. In clean energy alone, 20 regional non-profits have sprung up around the USA in the past three years to coordinate funding and product-launching efforts among companies, universities, entrepreneurs and state agencies.

Now, the federal government is stepping in. President Obama's fiscal 2012 budget proposes a competition to identify 20 potential clusters that would receive a share of $2.5 billion in financial incentives. A separate program involving 16 U.S. agencies aims to advance existing industry hubs. With a report Friday showing job growth slowing, officials say funding for innovation is needed to expand payrolls.

Clusters "are becoming a central framework for how the federal government is engaging," says Assistant Secretary of Commerce John Fernandez.

Some critics say government efforts often fall short by trying to pick winners and losers in the marketplace or create clusters that don't have a sufficient base of companies. Officials in several states downplay such concerns and say they must act to revive a fading manufacturing base. The U.S. lost 2 million factory jobs in the recent recession. Manufacturing employment in the U.S. peaked at about 19 million in 1970, when it made up 21% of the workforce. Today, the USA's 11.7 million factory workers are just 9% of all payrolls, though employment rebounded some in the recovery.

The U.S., with 19.4% of global factory output, was marginally overtaken by China last year as the world's manufacturing leader, according to IHS Global Insight. Cluster development is designed to attract firms and make them less likely to flee for countries with low labor costs or short-term financial incentives.

"Business as usual is broken," says Brookings Institution senior fellow Mark Muro, noting enticing firms with tax breaks alone yields limited benefit.

Cluster theory holds that manufacturers and suppliers often want to be in proximity to collaborate on product design. Companies want to be near universities to benefit from the latest innovations. And bigger clusters attract still more companies that seek access to a large pool of skilled workers.

The class Nudelman attends underscores the synergies of Cleveland's biomedical ecosystem. A year ago, Cuyahoga Community College started the class, which teaches computer-controlled milling to aspiring medical-device and aerospace workers, to supply area firms with more workers at the request of BioEnterprise, a non-profit charged with growing the cluster. The Labor Department kicked in a $600,000 grant, making the class free for students, many of whom lost old-line manufacturing jobs.

BioEnterprise CEO Baiju Shah says business leaders and local officials launched his and other non-profits around the 2001 recession when they realized Cleveland's traditional factory jobs weren't coming back. The Cleveland area has lost 80,000 manufacturing jobs since 2000, according to the Bureau of Labor Statistics.

Officials decided to base the area's future on an existing hub of medical imaging and other device makers — as well as pharmaceutical developers and bioscience researchers — and the presence of the renowned Cleveland Clinic and Case Western Reserve University. Until recently, the cluster had failed to draw the start-up firms and venture capital needed to create jobs, Shah says.

State support

Driving the effort was Ohio's Third Frontier, a $2.3 billion state program to nurture new tech-based industries. The initiative has pumped $235 million into biomedical research and start-ups in northeast Ohio since 2002. Non-profits such as BioEnterprise have recruited medical firms to the region, helped start-ups obtain venture capital and state money and matched manufacturers with suppliers.

Since 2001, the number of biomedical firms in the area has more than doubled to 600, and venture capital investments have swelled to an average $150 million a year since 2005, vs. $30 million a year from 1996 to 2001, according to BioEnterprise. The ventures employ a few thousand, a fraction of the jobs lost, but more are expected as fledgling firms grow.

On Euclid Avenue, an unpretentious artery that connects downtown Cleveland with uptown hospitals and universities, shuttered red-brick factories and social-service agencies are interspersed with tony health care office complexes with names such as CleveMed.

Nearby, ground was broken early this year on the $465 million Cleveland Medical Mart & Convention Center, the world's first marketplace for medical industry buyers and sellers.

BioEnterprise is the cluster's nerve center. In earth-toned open offices, venture capitalists sit in windowed cubicles along the perimeter; BioEnterprise marketers toil in the center.

Across the hall is an incubator with 19 biomedical start-ups, which pay nominal rents to BioEnterprise, and in some cases, share offices. One, CardioInsight, developed a vest with sensors to capture electrical signals from 250 body areas to better diagnose weak spots in the heart.

The vest was the brainchild of a Case Western graduate student and partly funded by Third Frontier and a local non-profit venture capitalist called JumpStart. The original prototype was a 15-pound medieval-looking garment strewn with wires. A local design firm, Nottingham Spirk, situated three blocks from CardioInsight, turned it into a lightweight, disposable vest with 250 printed circuits. "The fact that they were five minutes away allowed us to have multiple face-to-face meetings," says CardioInsight CEO Steve Arless. "You need to not only see it, you need to feel it."

The firm could double its 20-person staff in two years after the vest is cleared by regulators.

Nottingham has invented consumer products such as the Dirt Devil vacuum cleaner and a $5 battery-operated toothbrush. Located in a former church, the firm — whose designers rim a rotunda while technicians build prototypes in a workshop a few steps below — has doubled the medical-device portion of its portfolio to about 40%. "We read the tea leaves," says partner John Nottingham, who often stands beside surgeons during operations to see how tools can be improved.

Cleveland also has wrested biomedical start-ups from far-flung locales. In 2002, city and business officials went to Israel to lure Simbionix, a maker of computers that simulate surgery for medical students.

The simulators are made by Astro Manufacturing & Design, which has long produced auto and aerospace parts for other companies but is increasingly cranking out medical devices. In a quiet workshop off the whirring aerospace factory, two former industrial machine workers assemble computers and connect them to syringes and scalpels. They learned on the job.

"I don't know anything about the heart or lower arteries," says worker Ken Valardo, 53.

At another Astro plant nearby, employees make the screws and plates that go into broken spines and bones. That required a culture shift and more exacting procedures. Titanium rods are labeled and stored behind a locked gate until they're ready to be shaped. That way, finished goods can be tracked in case defects are found and a lot has to be recalled. Parts are sandblasted and inspected under microscopes for tiny imperfections.

Don Perish, a lanky, graying 52-year-old, has been turning out bone screws since he lost his job making auto industry tools two years ago. His margin for error is much smaller as he programs computer-controlled lathes to shape the screws to within a human-hair's width of the prescribed dimension. He also has to keep meticulous records of everything he does.

"You have to pay more attention," he says. In his old job, "If I dropped something on the floor, you'd just put it back and keep on going." Perish, whose hourly pay of about $17 an hour hasn't changed, says his new gig is more rewarding. "I know I'm helping somebody out who might otherwise be paralyzed."

Astro officials meet weekly with physicians at the Cleveland Clinic to work on new products. One recent morning, Astro executive Brett Crawford sat at a table in the office of orthopedist Joseph Iannotti to discuss ways to improve a long metal tool they're developing to guide surgeons during shoulder implants.

"The problem is the foot piece," Iannotti said, noting that the device's lower part didn't line up with a badly degenerated shoulder as he held it against a model. Crawford nodded and took notes: "We're doubling the (foot piece's) length." A new version was ready in three days.

Some skills in short supply

There are challenges, including a shortage of skilled workers and entrepreneurs to lead start-ups. Astro, with 275 employees, added 45 last year and is struggling to hire a dozen engineers, managers and machinists. "It's impossible," says Vice President Rich Peterson, adding that many old-line workers lack essential math and computer skills.

Also, U.S. approval of medical devices can take years. AxioMed, a Cleveland area start-up, has been selling its artificial spinal discs in Europe for 18 months but doesn't expect federal Food and Drug Administration approval until 2012, delaying a planned expansion from 15 to 30 employees. "It's much more difficult in the U.S.," says CEO Patrick McBrayer.

To hedge the region's bets, another non-profit called NorTech is working to develop clusters in clean energy and flexible electronics, which involves putting tiny, malleable printed circuit boards on clothing and other products so ski goggles, for example, can tint with a touch. "If biosciences starts to dip, others can pick up," says NorTech President Rebecca Bagley.

The flexible electronics cluster has only 20 firms, but it's attracted $60 million in state funding, and virtually no other region has a foothold in the space. By contrast, Harvard's Institute for Strategy and Competitiveness lists at least 40 medical-device clusters in the USA.

Critics say cluster development is misguided. Consultant Gary Kunkle says his study of 1.3 million firms showed success or failure is based on companies' distinctive qualities, not location. And, he says, governments are far more likely than the marketplace to fund lemons. "You have a bureaucracy that has no idea about the feasibility of these ideas," he says, noting nearly every state has been trying to form a biotech cluster.

Norman Chagnon, executive director of Ohio's Third Frontier, says officials are simply trying to hasten the development of industries and companies that have obvious strengths. "It would have been foolish and hubris for us to pick an area that's hot and say that's where we're going to go," he says.

Mr. Bullock is a leader in the cardiac rhythm management field and most recently served as Chief Executive Officer of Atritech, an electrophysiology company that was acquired by Boston Scientific earlier this year. Previously, Mr. Bullock served as the Chief Executive Officer of Endocardial Solutions, a catheter-based cardiac mapping company that was acquired by St. Jude Medical in 2005.

"I'm excited to be joining CardioInsight's Board of Directors and am looking forward to working with their team to commercialize this innovative new product," said Mr. Bullock. "CardioInsight's non-invasive cardiac mapping system represents an important evolution in the field of cardiac mapping and addresses a number of significant clinical opportunities to improve the diagnosis and treatment guidance for cardiac arrhythmias and heart failure."

CardioInsight's ECVUE™ mapping technology, which non-invasively generates real time, 3-D images of the electrical activity of the heart by combining body surface electrical data with anatomical data obtained from imaging scans is planned for commercial introduction in Europe later this year. A statewide launch is expected to follow in 2012.

"Jim's track record of commercializing innovative electrophysiology products speaks for itself," said Steve Arless, CardioInsight's Chief Executive Officer. "His direct experience and insight into the cardiac mapping market will be an invaluable resource as we prepare to launch our mapping system later this year."

Contact Information:

Steve Arless, CEO
CardioInsight Technologies Inc.
216.453.5950 - sarless@cardioinsight.com

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology called Electrocardiographic Mapping (ECM) that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. ECM non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3-D anatomical data obtained from imaging scans. The CardioInsight system reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. The ability of ECM to generate accurate images of the heart’s electrical activity and its potential to guide therapy in both cardiac arrhythmias and congestive heart failure has been demonstrated in over 300 patient studies sponsored by the Company.